

# Index

## AUTHORS

### A

Ades T, 199–204, 211–212 (Editorial), 316–320  
Anderson WF, 367–370  
Averette HE, 92–114

### B

Bal DG, 11–14 (Guest Editorial)  
Bennett JM, 327–328 (Guest Editorial)  
Brawley O, 367–370  
Brooks D, 38–75  
Brown J, 153–181  
Byers T, 38–75, 153–181

### C

Canto MT, 367–370  
Clive-Bumpus RE, 119–130  
Cohen C, 38–75  
Cokkinides V, 38–75  
Creasman W, 38–75

### D

Donaldson SS, 119–130  
Doyle C, 153–181  
Durie BGM, 271–272 (Guest Editorial)

### E

Egan K, 142–143  
Eldridge B, 153–181  
Eyre HJ, 3–6 (Editorial), 38–75, 151–152 (Editorial), 211–212 (Editorial)

### F

Ferrecio C, 349–364  
Fremgen AM, 119–130  
Frumkin H, 137–141, 193–198, 254–262, 337–344

### G

Gansler T, 3–6 (Editorial), 137–141, 199–204, 211–212 (Editorial)  
Given BA, 213–231  
Given CW, 213–231  
Greenlee RT, 15–36

### H

Haase GM, 119–130  
Harpham WS, 131–136

Hejna M, 290–315  
Herrero R, 349–364  
Hill-Harmon MB, 15–36  
Hutchison C, 119–130

### J

Jacobson A, 137–141  
Janicek MF, 92–114

### K

Köstler WJ, 290–315  
Kozachik S, 213–231

### L

Lazcano-Ponce EC, 349–364  
Levin B, 38–75

### M

McDaniel RW, 232–248  
Miller M, 199–204  
Miquel JF, 349–364  
Muñoz N, 349–364  
Murphy SB, 119–130  
Murray T, 15–36

### N

Nervi F, 349–364

### P

Provost AJ, 119–130

### R

Rhodes VA, 232–248  
Rosenthal DS, 199–204, 316–320  
Rothenberger D, 38–75  
Rubin SC, 89–91 (Guest Editorial)  
Ruiz PA de, 349–364  
Runowicz C, 38–75

### S

Samet JM, 337–344  
Saslow D, 38–75  
Shochat SJ, 119–130  
Smith RA, 38–75

### T

Thompson K, 153–181  
Thun MJ, 15–36, 137–141, 193–198, 254–262

# Index

## AUTHORS

### A

Ades T, 199–204, 211–212 (Editorial), 316–320  
Anderson WF, 367–370  
Averette HE, 92–114

### B

Bal DG, 11–14 (Guest Editorial)  
Bennett JM, 327–328 (Guest Editorial)  
Brawley O, 367–370  
Brooks D, 38–75  
Brown J, 153–181  
Byers T, 38–75, 153–181

### C

Canto MT, 367–370  
Clive-Bumpus RE, 119–130  
Cohen C, 38–75  
Cokkinides V, 38–75  
Creasman W, 38–75

### D

Donaldson SS, 119–130  
Doyle C, 153–181  
Durie BGM, 271–272 (Guest Editorial)

### E

Egan K, 142–143  
Eldridge B, 153–181  
Eyre HJ, 3–6 (Editorial), 38–75, 151–152 (Editorial), 211–212 (Editorial)

### F

Ferrecio C, 349–364  
Fremgen AM, 119–130  
Frumkin H, 137–141, 193–198, 254–262, 337–344

### G

Gansler T, 3–6 (Editorial), 137–141, 199–204, 211–212 (Editorial)  
Given BA, 213–231  
Given CW, 213–231  
Greenlee RT, 15–36

### H

Haase GM, 119–130  
Harpham WS, 131–136

Hejna M, 290–315  
Herrero R, 349–364  
Hill-Harmon MB, 15–36  
Hutchison C, 119–130

### J

Jacobson A, 137–141  
Janicek MF, 92–114

### K

Köstler WJ, 290–315  
Kozachik S, 213–231

### L

Lazcano-Ponce EC, 349–364  
Levin B, 38–75

### M

McDaniel RW, 232–248  
Miller M, 199–204  
Miquel JF, 349–364  
Muñoz N, 349–364  
Murphy SB, 119–130  
Murray T, 15–36

### N

Nervi F, 349–364

### P

Provost AJ, 119–130

### R

Rhodes VA, 232–248  
Rosenthal DS, 199–204, 316–320  
Rothenberger D, 38–75  
Rubin SC, 89–91 (Guest Editorial)  
Ruiz PA de, 349–364  
Runowicz C, 38–75

### S

Samet JM, 337–344  
Saslow D, 38–75  
Shochat SJ, 119–130  
Smith RA, 38–75

### T

Thompson K, 153–181  
Thun MJ, 15–36, 137–141, 193–198, 254–262

**U**

Urista GA, 349-364

**V**

Vesole DH, 273-285

von Eschenbach AC, 38-75

**W**

Wender R, 38-75

Wenzel C, 290-315

Williams AM, 153-181

Winchester DP, 119-130

Wistuba II, 349-364

**Y**

Yates JW, 329-336

**Z**

Zaidi AA, 273-285

Zielinski CC, 290-315

**SUBJECTS****A****Acetaminophen***Ovarian cancer risk*, 323-324 (*News & Views*)**Acupuncture/acupressure***Nausea and vomiting management*, 244-245**Adenomatous polyps***Colorectal cancer, ACS early detection guidelines*, 44-54**Advertising***Tobacco smoking and children*, 324-326 (*News & Views*)**Age level***Childhood cancer*, 121-123*Nausea and vomiting*, 236-237**Agency for Toxic Substances and Disease Registry (ATSDR)***Radon exposure*, 342**Aging.** See also Comorbidity in geriatric oncology research*Cancer and aging: Why not waltz together?*, 327-328  
(*Guest Editorial*)**Alcohol***Cancer prevention, study on*, 266 (*News & Views*)*Comorbidity in geriatric oncology research*, 331*Nausea and vomiting*, 237*Nutrition*, 162**Allogenic bone marrow transplant***Multiple myeloma*, 280-281**Allopurinol***Oral mucositis*, 309**Alternative methods.** See Complementary and alternative methods (CAM)**American Cancer Society***CA Web site improvements*, 270*Mission statement of*, 3*Nutrition guidelines*, 155, 156*Professional opportunities with*, 37, 371*UICC International Fellowships for Beginning Investigators (ACSBI)*, 188*Workgroup Grading System for Evaluating Benefit versus Harm*, 168**American Cancer Society early detection guidelines***38-75. See also Early detection**Cancer-related check-up*, 64-70*Colorectal cancer*, 44-54*Continuing Medical Education Activity*, 77-80*Endometrial cancer*, 54-59*Lung cancer*, 59-64*Overview*, 38-41*Patient page for*, 87-88*Prostate cancer*, 41-44, 150 (*Erratum*), 209 (*News & Views*), 373 (*Erratum*)**Amifostine***Oral mucositis*, 308**Analgesics***Acetaminophen, ovarian cancer risk*, 323-324 (*News & Views*)**Anemia***Comorbidity in geriatric oncology research*, 331*Multiple myeloma*, 277**Announcements***American Cancer Society, professional opportunities with*, 37, 371*UICC International Fellowships for Beginning Investigators (ACSBI)*, 188**Antibacterial agents***Oral mucositis*, 303**Antiemetics***Nausea and vomiting, management of*, 243**Antifungal agents***Oral mucositis*, 302**Anti-inflammatory agents***Oral mucositis*, 304-306**Antimicrobial agents***Oral mucositis*, 302**Antisense drug***Chemoresistant melanomas*, 8-9 (*News & Views*)**Antiseptic agents***Oral mucositis*, 307**Antiviral agents***Oral mucositis*, 302-303**Arsenic**, 254-262*Carcinogenicity of*, 257-259*Chemical forms of*, 254-255*Exposure sources*, 255-257

Patient advice, 260–262  
Public policy issues, 259–260

**Aspergillosis**

Oral mucositis, 302

**Aspirin**

*Acetaminophen, ovarian cancer risk, 323–324 (News & Views)*

**Augmerosen**

*Chemoresistant melanomas, 8–9 (News & Views)*

**Autologous transplants**

*Multiple myeloma, 279–280*

**Azelastine**

Oral mucositis, 308–309

**B****Bacterial infection**

Oral mucositis, 302, 303

**Basic research**

*Cancer statistics, directions in, 12 (Guest Editorial)*

*CA new directions, 5*

**Benzydamine**

Oral mucositis, 304

**Beta carotene**

Oral mucositis, 308

**Bethesda System**

*Cervical cancer, 97–98*

**Black cohosh (*Cimicifuga racemosa*)**

*Breast cancer, complementary and alternative methods (CAM), 317–318*

**Body weight**

*Nutrition, 159*

**Bone marrow transplant**

*Multiple myeloma, 280–281*

**Bone scans**

*Cervical cancer, monitoring for recurrence, 108*

**Brain tumor**

*Cellular phone and risk of, 137–141*

*Molecular biology, 7 (News & Views)*

**Breast cancer**

*ACS early detection guidelines, 65*

*Black cohosh (*Cimicifuga racemosa*), complementary and alternative methods (CAM), 317–318*

*Comorbidity in geriatric oncology research, 331*

*Estrogen replacement therapy, 83–84 (News & Views)*

*Mortality rates, by geography and race, 367–370*

*Nutrition, 167–170*

*Screening data, 67*

*Self-examination importance, 268–270 (News & Views)*

**Breast reconstruction surgery**

*Tobacco smoking complicates, 149–150 (News & Views)*

**Bronchoscopy**

*Lung cancer, ACS early detection guidelines, 62*

**C****CA — A Cancer Journal for Clinicians**

*New directions in 2001, 3–6 (Editorial)*

*Web site improvements, 270*

**Caloric intake**

*Nutrition, 158–159*

**Cancer pain.** See Pain control

**Cancer prevention.** See also American Cancer Society  
early detection guidelines; Early detection

*Cancer statistics, directions in, 12 (Guest Editorial)*

*CA new directions, 3–4*

*Cervical cancer, 90 (Guest Editorial)*

*Molecular biology, 7–10 (News & Views)*

*Nutrition, 175*

*Study on, 265–267 (News & Views)*

**Cancer-related check-up**

*ACS early detection guidelines, 64–70*

**Cancer screening**

*ACS early detection guidelines, cancer-related check-up, 64–70*

*Breast cancer, self-examination, 268–270 (News & Views)*

*Cancer prevention, study on, 266 (News & Views)*

*Cancer statistics, directions in, 12 (Guest Editorial)*

*Cervical cancer, 90 (Guest Editorial), 97–102*

*Colorectal, DNA stool test, 8 (News & Views)*

*Physician/patient communications, 85 (News & Views)*

**Cancer statistics, 15–36**

*Childhood cancer, 27–29, 119–120*

*Directions in, 11–14 (Guest Editorial)*

*Distribution, by race and stage at diagnosis, US, 34*

*Estimated new cases, by gender, 16*

*Estimated new cases, by site and gender, 18*

*Estimated new cases, by site and state, US, 17*

*Findings, 18–25*

*Incidence, by age, gender, and site, US, 21, 22*

*Incidence, by gender, US, 20*

*Incidence, by site, race, and ethnicity, 33*

*Limitations and challenges, 29*

*Methods, 15–18*

*Mortality rates, breast cancer, by geography and race, 367–370*

*Mortality rates, by age, gender, and site, US, 27, 28, 144 (Erratum)*

*Mortality rates, by gender, US, 23*

*Mortality rates, by gender, US, historical, 26*

*Mortality rates, by site, race, and ethnicity, 33*

**Mortality rates, by site and gender, US,** 25  
**Mortality rates, by site and state, US,** 24  
**Mortality rates, gallbladder cancer,** 352–354  
**Mortality rates, leading causes of death, children, US,** 36  
**Mortality rates, leading causes of death, US,** 29  
**Mortality rates, leading causes of death by age and gender, US,** 30  
**Mortality rates, leading causes of death by cancer, by site and gender, US,** 31, 32  
**Mortality rates, trends in, by site and gender, US,** 32  
**Probability of developing cancer, by age and gender,** 19  
**Race/ethnicity,** 25–27  
*Survival, by race and stage at diagnosis, US,* 34, 373  
*(Erratum)*  
*Survival, trends in, by race and year of diagnosis, US,* 35  
**Candidiasis**  
*Oral mucositis,* 302  
**Cannabinoids**  
*Nausea and vomiting, management of,* 243–244  
**Capsaicin**  
*Oral mucositis,* 307  
**Cardiac disease**  
*Comorbidity in geriatric oncology research,* 331  
**Caregivers.** See Family caregiver support  
**Cellular biology**  
*CA new directions,* 5  
**Cellular phone**  
*Brain tumor risk,* 137–141  
**Cervical cancer,** 92–114  
*ACS early detection guidelines,* 65  
*Cancer prevention, study on,* 266 (News & Views)  
*Chemoprevention,* 108–109  
*Clinical versus surgical staging,* 102–104  
*Continuing Medical Education Activity,* 115–118  
*Epidemiology,* 94  
*Human immunodeficiency virus (HIV),* 96–97  
*Human papilloma virus (HPV),* 94–96  
*Immunotherapy,* 110  
*Management,* 104–107  
*Management, recurrent disease,* 107–108  
*Monitoring for recurrence,* 108  
*Overview,* 92–93  
*Pretreatment evaluation for invasive,* 102  
*Risk factors,* 93–94  
*Screening and detection,* 97–102  
*Screening data,* 67–68  
*Successes and failures,* 89–91 (Guest Editorial)  
*Vaccination,* 109–110  
**Chamomile**  
*Oral mucositis,* 304  
**Chemoprevention**  
*Cervical cancer,* 108–109

**Chemotherapy.** See also Oral mucositis  
*Cervical cancer,* 105–108  
*Comorbidity in geriatric oncology research,* 331  
*Folic acid and,* 164  
*Molecular biology,* 7–10 (News & Views)  
*Multiple myeloma,* 278–279, 282–283  
*Nausea and vomiting related to, neuropathophysiology of,* 234–236  
*Oral mucositis,* 290–315  
**Chest X-ray**  
*Cervical cancer, monitoring for recurrence,* 108  
*Lung cancer, ACS early detection guidelines,* 60–61  
**Childhood cancer,** 119–130  
*Cancer statistics,* 27–29, 30  
*Computed tomography, reduced radiation, cancer risk in later life,* 84–85 (News & Views)  
*Diagnostic groups,* 121  
*Ethnic differences,* 121–123  
*Insurance coverage,* 123  
*Methods and materials,* 120–121  
*Overview,* 119–120  
*Protocol participation,* 124–128  
*SEER Program,* 121  
**Children**  
*Computed tomography, reduced radiation, cancer risk in later life,* 84–85 (News & Views)  
*Tobacco smoking, advertising and,* 324–326 (News & Views)  
**Chlorhexidine**  
*Oral mucositis,* 309  
**Cholecystectomy**  
*Gallbladder cancer,* 361  
**Cigarette smoking.** See Tobacco smoking  
**Cimicifuga racemosa (black cohosh)**  
*Breast cancer, complementary and alternative methods (CAM),* 317–318  
**Clinical trials**  
*Comorbidity in geriatric oncology research,* 332–334  
**Colitis**  
*Colorectal cancer, ACS early detection guidelines,* 51  
**Colonoscopy**  
*Colorectal cancer, ACS early detection guidelines,* 46, 47–52, 65  
**Colorectal cancer**  
*ACS early detection guidelines,* 44–54, 65  
*Cancer prevention, study on,* 266 (News & Views)  
*Comorbidity in geriatric oncology research,* 331  
*Continuing Medical Education Activity,* 77–80  
*Hereditary nonpolyposis (HNPCC), endometrial cancer, ACS early detection guidelines,* 57, 58–59  
*Nutrition,* 174  
*Screening, DNA stool test,* 8 (News & Views)

**Screening data, 67**

*Smoking linked to risk of, 9 (News & Views)*

**Comorbidity in geriatric oncology research, 329–336**

- Age-related factors, 331–332*
- Cancer and aging: Why not waltz together?, 327–328 (Guest Editorial)*
- Clinical trials, 332–334*
- Information sources, 332*
- Measurement, 334–336*
- Overview, 329–330*
- Types of conditions, 330–331*

**Complementary and alternative methods (CAM).** See also Nutrition

- Black cohosh (*Cimicifuga racemosa*), breast cancer, 317–318*
- CA new directions, 5*
- Nutrition, 162–163, 165–167*
- PC-SPES, 199–204*
- Perioperative complications, herbal supplements may increase risk of, 319–320*
- Physician/patient communications, 131–136*
- Prostate cancer, flaxseed and low-fat diet, 318–319*
- Vitamin C, genotoxic lipid metabolites promoted by, 316–317*

**Computed tomography**

- Cervical cancer, monitoring for recurrence, 108*
- Lung cancer, ACS early detection guidelines, 61, 63, 64*
- Reduced radiation, cancer risk in later life, 84–85 (News & Views)*

**Computed tomography colonography**

- Colorectal cancer, ACS early detection guidelines, 46–47*

**Computerized screening**

- Pap smear, cervical cancer, 99–100*

**Continuing Medical Education Activity**

- ACS early detection guidelines, 77–80*
- Cervical cancer, 115–118*
- Multiple myeloma, 286–289*
- Nausea and vomiting, 249–252*
- Nutrition, 189–192*
- Radon exposure, 345–348*

**COPE model**

- Family caregiver support, 225*

**Corticosteroids**

- Oral mucositis, 307*

**Crohn's disease**

- Colorectal cancer, ACS early detection guidelines, 51*

**Cryotherapy**

- Oral mucositis, 301–302*

**Cytokines**

- Oral mucositis, 306*

---

**D**

**Depression**

- Comorbidity in geriatric oncology research, 331*

**Dexpanthenol**

- Oral mucositis, 307*

**Diabetes**

- Comorbidity in geriatric oncology research, 331*
- Endometrial cancer, ACS early detection guidelines, 57*

**Diagnostic groups**

- Childhood cancer, 121*

**Diesel exhaust**

- Environmental carcinogens, 193–198*

**Diet.** See Nutrition

**Dietary fats**

- Nutrition, 159–160*

**Digital rectal examination (DRE)**

- Colorectal cancer, ACS early detection guidelines, 46*
- Prostate cancer, ACS early detection guidelines, 39–44*

**DNA repair enzyme**

- Molecular biology, 7 (News & Views)*

**DNA stool test**

- Colorectal screening, molecular biology, 8 (News & Views)*

**Double contrast barium enema (DCBE)**

- Colorectal cancer, ACS early detection guidelines, 46, 47–53*

**Drug abuse**

- Cancer prevention, study on, 266 (News & Views)*

---

**E**

**Early detection.** See also American Cancer Society

- early detection guidelines; Cancer prevention American Cancer Society guidelines, 38–75*
- Breast cancer, importance of, 268–270 (News & Views)*
- CA, new directions, 3–4*
- Cancer statistics, directions in, 12 (Guest Editorial)*
- Ovarian cancer, diagnosis and prognosis in, 10 (News & Views)*
- Study on, 265–267 (News & Views)*

**Editorials**

- CA — A Cancer Journal for Clinicians, new directions in 2001, 3–6 (Editorial)*
- Cancer and aging: Why not waltz together?, 327–328 (Guest Editorial)*
- Cancer statistics, directions in, 11–14 (Guest Editorial)*
- Cervical cancer successes and failures, 89–91 (Guest Editorial)*
- Multiple myeloma, new perspectives on, 271–272 (Guest Editorial)*
- Nutrition advice, 151–152*

**Quality-of-life issues, communication with patients about,** 211-212

**Emphysema**

- Comorbidity in geriatric oncology research*, 331

**Endometrial biopsy**

- Endometrial cancer, ACS early detection guidelines*, 55, 56

**Endometrial cancer**

- ACS early detection guidelines*, 54-59
- Continuing Medical Education Activity*, 77-80

**Environmental carcinogens.** See also Occupational exposure

- Arsenic, 254-262
- Brain tumor risk, cellular phone and, 137-141
- CA new directions, 4
- Diesel exhaust, 193-198
- Radon, 337-344

**Epidemiology**

- CA new directions, 4

**Erectile dysfunction**

- Prostate cancer treatments*, 148-149 (*News & Views*)

**Errata**

- Cancer statistics, mortality rates, by age, gender, and site, US, 27, 144
- Cancer statistics, survival, by race and stage at diagnosis, US, 373
- Nausea, vomiting, and retching, pharmacologic management, 320
- Nutrition, head and neck cancers, 320
- Prostate cancer, ACS early detection guidelines, 150, 373
- Prostate cancer, external beam radiation therapy for, 144

**Estrogen replacement therapy.** See also Hormone replacement therapy

- Cancer risk, 83-84 (*News & Views*)
- Long-term, ovarian cancer risk and, 147-148 (*News & Views*)

**Ethnic differences in cancer statistics**

- Breast cancer, mortality rates, by geography and race, 367-370
- Cancer screening data, 66, 68-69
- Cancer statistics, directions in, 12-13 (*Guest Editorial*)
- Childhood cancer, 121-123
- Distribution, by race and stage at diagnosis, US, 34
- Incidence, 25-27, 33
- Mortality rates, 33
- Survival, by race and stage at diagnosis, US, 34
- Survival, trends in, by race and year of diagnosis, US, 35

**Exercise**

- Nutrition, 160-162

**External beam radiation therapy**

- Prostate cancer, 144 (*Erratum*)

**F**

**Familial adenomatous polyposis syndrome (FAP)**

- Colorectal cancer, ACS early detection guidelines*, 51

**Family caregiver support**, 213-231

- Caregiver information and assistance needs, 219
- Caregiver reactions, 219-223
- Comfort needs, 216-217
- Direct versus indirect care, 215-216
- Focus of, 214-215
- Future research, 228-229
- Interventions, COPE model, 225
- Interventions, education and information, 223-225
- Interventions, planning and implementation, 223
- Interventions, psychoeducational program, 225-226
- Interventions, psychotherapy, 226-227
- Mobilization of resources, 227-228
- Multiple roles, balancing of, 228
- Overview, 213-214
- Pain control, 217-218
- Quality-of-life issues, communication with patients about, 211-212 (*Editorial*)

**Fasting therapy**

- Nutrition, 163

**Fecal occult blood test (FOBT)**

- Colorectal cancer, ACS early detection guidelines*, 44-46, 47-52

**Fish oil**

- Nutrition, 166

**5-HT<sub>3</sub> receptor antagonists**

- Nausea and vomiting, management of, 240, 242

**Flaxseed**

- Prostate cancer, complementary and alternative methods (CAM)*, 318-319

**Flaxseed oil**

- Nutrition, 166

**Flexible sigmoidoscopy**

- Colorectal cancer, ACS early detection guidelines*, 46, 47-52, 65

**Fluorescence bronchoscopy**

- Lung cancer, ACS early detection guidelines*, 62

**Folic acid**

- Methotrexate and, 164

**Follow-up examination**

- Melanoma, improves survival of second, 207-208 (*News & Views*)

**Food safety**

- Guidelines for, 158

**Fruits and vegetables**

- Nutrition, 160

**Fungal infection**

- Oral mucositis, 302

**G**

**Gallbladder cancer**, 349–364

- Incidence rates, data sources for estimation of*, 350–352
- Molecular pathology*, 356–357
- Morphology and pathogenesis*, 354–356
- Mortality rates*, 352–354
- Overview*, 349–350
- Perspectives on*, 361–362
- Prevention and future trends*, 360–361
- Risk factors*, 358–360

**Gallstones**

- Gallbladder cancer risk*, 358–360

**Gastric cancer**

- Nutrition*, 173–174

**Gender**

- Childhood cancer*, 121–123
- Nausea and vomiting*, 236–237

**Genetics**

- Gallbladder cancer risk*, 360

**Ginger**

- Nutrition*, 166–167

**Glioma**

- Molecular biology*, 7 (*News & Views*)

**Glutamine**

- Oral mucositis*, 306

**Granulocyte colony-stimulating factor (G-CSF)**

- Oral mucositis*, 306–308

**Granulocyte macrophage colony-stimulating factor (GM-CSF)**

- Oral mucositis*, 306–308

**H**

**Head and neck cancers**

- Nutrition*, 173, 320 (*Erratum*)

**Heart disease**

- Estrogen replacement therapy*, 83 (*News & Views*)
- Estrogen replacement therapy, long-term, risk factors*, 148 (*News & Views*)

**Heat shock protein (HSP) vaccines**

- Cervical cancer*, 110

**Hereditary nonpolyposis colorectal cancer (HNPPC)**

- Endometrial cancer, ACS early detection guidelines*, 57, 58–59

**Hereditary non-polyposis colorectal cancer (HNPPC) syndrome**

- Colorectal cancer, ACS early detection guidelines*, 51

**Herpes simplex virus (HSV)**

- Oral mucositis*, 302–303

**Histocompatibility antigens**

**Cervical cancer**, 96

**Hormone replacement therapy.** See also Estrogen replacement therapy

*Endometrial cancer, ACS early detection guidelines*, 56

**Hot flashes**

*Breast cancer, black cohosh (Cimicifuga racemosa), CAM*, 317–318

**Human immunodeficiency virus (HIV)**

*Cervical cancer*, 96–97, 110

**Human papilloma virus (HPV)**

*Cervical cancer*, 90 (*Guest Editorial*), 92–96, 97, 98–99, 109

**Hydrogen peroxide**

*Oral mucositis*, 309–310

**Hygiene**

*Oral mucositis*, 294–295, 301

**I**

**Immunoglobulins**

*Oral mucositis*, 309

**Immunotherapy**

*Cervical cancer*, 110

**Induction therapy**

*Multiple myeloma*, 282

**Infection**

*Gallbladder cancer risk*, 360

*Multiple myeloma*, 277

**Infertility**

*Endometrial cancer, ACS early detection guidelines*, 57

**Inflammatory bowel disease**

*Colorectal cancer, ACS early detection guidelines*, 51

**Insurance coverage**

*Childhood cancer*, 123

**Interferon**

*Multiple myeloma*, 281–282

**International Agency for Research on Cancer (IARC)**

*Radon exposure*, 342

**International Union Against Cancer**

*International Fellowships for Beginning Investigators (ACSBI)*, 188

**J**

**Juice therapy**

*Nutrition*, 163

**L**

**Laser treatment**

*Oral mucositis*, 304

**Late menopause***Endometrial cancer, ACS early detection guidelines, 56***Liquid-based sampling techniques***Pap smear, cervical cancer, 100-101***Local anesthetics***Oral mucositis, 303-304***Low-radiation-dose computed tomography***Lung cancer, ACS early detection guidelines, 61***Lung cancer.** See also Radon*ACS early detection guidelines, 59-64**Diesel exhaust, 194-197**Nutrition, 172-173**Radon exposure, 337, 341, 342***M****Macrobiotic diets***Nutrition, 163***Mammogram***Breast cancer, ACS early detection guidelines, 65**Breast cancer, self-examination, 268-270 (News & Views)***Media***CA new directions, 6**Tobacco smoking, 142-144***Melanomas***Chemoresistant, antisense drug enhances response, 8-9 (News & Views)**Follow-up exams improve survival of second, 207-208 (News & Views)***Menopause***Endometrial cancer, ACS early detection guidelines, 56***Methotrexate***Folic acid and, 164***Metoclopramide***Nausea and vomiting, management of, 243-244***MGMT***Molecular biology, 7 (News & Views)***Molecular biology***CA new directions, 5**Cervical cancer, HPV, 95**Chemotherapy and prevention, 7-10 (News & Views)**Gallbladder cancer, 356-357***Molecular screening***Lung cancer, ACS early detection guidelines, 62***Mucormycosis***Oral mucositis, 302***Mucosatoxic therapy***Oral mucositis, 295, 301***Multiple myeloma***Allogenic bone marrow transplant, 280-281**Autologous transplants, 279-280**Chemotherapy, 278-279**Continuing Medical Education Activity, 286-289**Definition and characteristics, 273**Diagnosis, 276**Epidemiology, 274-275**Etiology, 274**Future directions, 282-283**Laboratory evaluation, 275-276**Maintenance therapy, 281-282**New perspectives on, 271-272 (Guest Editorial)**Signs and symptoms, 275**Staging, 276-277**Supportive care, 277-278***Muscle relaxation techniques***Nausea and vomiting management, 245***Music therapy***Nausea and vomiting management, 245***N****National Institute for Occupational Safety and Health (NIOSH)***Diesel exhaust, 196***National Toxicology Program (NTP)***Radon exposure, 341-342***Nausea, vomiting, and retching***Age and gender factors, 236-237**Alcohol effect, 237**Assessment of, 238-240, 241**Chemotherapy-related NVR, neuropathophysiology of, 234-236**Concomitant symptoms, 237**Continuing Medical Education Activity, 249-252**Management, acupuncture/acupressure, 244-245**Management, diet and environment, 244**Management, guided imagery, 245-246**Management, music therapy, 245**Management, pharmacologic, 240, 242-244, 320 (Erratum).**Management, progressive muscle relaxation, 245**Overview, 232-233**Patient expectations, 236**Patient page for, 253**Pharmacologic interactions, 238**Psychological factors, 236**Quality-of-life issues, communication with patients about, 211-212 (Editorial)**Signs versus symptoms, 233**Symptom components and dimensions, 233-234**Tumor burden, 237-238***NK-1 receptor antagonists***Nausea and vomiting, management of, 242-243*

**Non-Hodgkin's lymphoma**

*Complementary and alternative methods (CAM), 131–136*

**Nulliparity**

*Endometrial cancer, ACS early detection guidelines, 57*

**Nutrition.** See also Complementary and alternative methods (CAM)

*Advice, 151–152 (Editorial)*

*Alcohol, 162*

*Body weight changes, 159*

*Breast cancer, 167–170*

*Caloric intake, 158–159*

*Cancer prevention, 175*

*Colorectal cancer, 174*

*Complementary and alternative methods (CAM), 165–167*

*Continuing Medical Education Activity, 189–192*

*Decision-making, 175–176*

*Dietary fats, 159–160*

*Dietary supplements, 163–165*

*Food safety, 158*

*Fruits and vegetables, 160*

*Gastric cancer, 173–174*

*Head and neck cancers, 173, 320 (Erratum)*

*Lung cancer, 172–173*

*Nausea and vomiting management, 244*

*Overview, 153–155*

*Patient page for, 182–187*

*Phases, advanced cancer, 158*

*Phases, recovery, 157*

*Phases, recurrence prevention, second cancers, disease, 157–158*

*Phases, treatment, 155–157*

*Physical activity, 160–162*

*Prostate cancer, 170–172*

*Prostate cancer, complementary and alternative methods (CAM), 318–319*

*Regimens, 162–163*

*Vitamin C, genotoxic lipid metabolites promoted by, complementary and alternative methods (CAM), 316–317*

**O****Obesity**

*Endometrial cancer, ACS early detection guidelines, 57*

**Occupational exposure.** See also Environmental car-

cinogens

*CA new directions, 4*

*Gallbladder cancer risk, 360*

**Oral mucositis, 290–315**

*Antibacterial agents, 303*

*Antifungal agents, 302*

*Antimicrobial agents, 302*

*Antiviral agents, 302–303*

*Clinical trials (summary table), 296–301*

*Cryotherapy, 301–302*

*Experimental methods, 304–307*

*Incidence, pathogenesis, and predisposing factors, 290–293*

*Inefficacious approaches, 309–310*

*Local anesthetics, 303–304*

*Nonpharmacological methods (locally applied), 294–295, 301–302*

*Overview, 290*

*Pharmacotherapeutics (locally applied), 302–304*

*Pharmacotherapeutics (systemically applied), 307–309*

*Symptoms and diagnosis, 293*

**Ovarian cancer**

*Acetaminophen and risk, 323–324 (News & Views)*

*Diagnosis and prognosis in, 10 (News & Views)*

*Estrogen replacement therapy, long-term, risk factors, 147–148 (News & Views)*

**P****Pain control**

*Family caregiver support, 217–218*

*Patient page for, 365–366*

**Palliative care.** See Family caregiver support; Nausea, vomiting, and retching

**Pancreatic cancer**

*Obesity and inactivity increase risk of, 326 (News & Views)*

**Pap smear**

*Cervical cancer, 90 (Guest Editorial), 97–102*

*Cervical cancer, ACS early detection guidelines, 65*

*Cervical cancer, history, 92*

*Endometrial cancer, ACS early detection guidelines, 56*

**Patient expectations**

*Nausea and vomiting, 236*

**Patient pages**

*American Cancer Society early detection guidelines, 87–88*

*Nausea, vomiting, and retching, 253*

*Nutrition, 182–187*

*Pain control, 365–366*

**PC-SPES**

*Complementary and alternative methods (CAM), 199–204*

**Pentoxifylline**

*Oral mucositis, 309–310*

**Perioperative complications**

*Herbal supplements may increase risk of, complementary and alternative methods (CAM), 319–320*

**Phenothiazines**

*Nausea and vomiting, management of*, 243

**Physical activity**

- Nutrition*, 160-162

**Physician/patient communications**

- Arsenic exposure*, 260-262
- Cancer prevention, study on*, 265-267 (*News & Views*)
- Cancer screening*, 85 (*News & Views*)
- Complementary and alternative methods (CAM)*, 131-136
- Nutrition*, 175-176
- Prognosis, physician reticence on*, 267-268 (*News & Views*)
- Quality-of-life issues, communication with patients about*, 211-212 (*Editorial*)

**Polycystic ovary syndrome**

- Endometrial cancer, ACS early detection guidelines*, 57

**Povidone-iodine**

- Oral mucositis*, 307

**Prognosis**

- Physician reticence on*, 267-268 (*News & Views*)

**Progressive muscle relaxation**

- Nausea and vomiting management*, 245

**Propantheline**

- Oral mucositis*, 309

**Prostaglandin E<sub>2</sub>**

- Oral mucositis*, 305

**Prostate cancer**

- ACS early detection guidelines*, 39-44, 64, 65, 150  
*(Erratum)*, 373 (*Erratum*)
- Continuing Medical Education Activity*, 77-80
- Erectile dysfunction, treatments*, 148-149 (*News & Views*)
- Erratum*, 373
- External beam radiation therapy for*, 144 (*Erratum*)
- Flaxseed and low-fat diet, complementary and alternative methods (CAM)*, 318-319
- Nutrition*, 170-172
- PSA test detects aggressive cancers*, 208-209 (*News & Views*)
- Screening data*, 68

**Prostate specific antigen (PSA) test**

- ACS early detection guidelines*, 39-44, 64, 65
- Aggressive cancers detected early by*, 208-209 (*News & Views*)
- Screening data*, 68

**Psychological factors**

- Nausea and vomiting*, 236

**Psychotherapy**

- Family caregiver support*, 226-227

**Public policy issues**

- Arsenic*, 259-260

**Q****Quality-of-life issues**

- CA new directions*, 4-5
- Communication with patients about*, 211-212 (*Editorial*)
- Comorbidity in geriatric oncology research*, 333

**R**

**Radiation Exposure Compensation Act of 1990**, 343

**Radiation proctitis**

- Vitamins C and E diminish symptoms of*, 209-210  
*(News & Views)*

**Radiation shields**

- Oral mucositis*, 304

**Radiation therapy.** See also **Oral mucositis**

- Cervical cancer*, 105-108
- Comorbidity in geriatric oncology research*, 331
- Oral mucositis*, 290-315

**Radon**, 337-344

- Advice to patients and public*, 342-343
- Animal and laboratory studies*, 341
- Background*, 337
- Cancer association with*, 339
- Continuing Medical Education Activity*, 345-348
- Disease risks*, 342
- Epidemiologic evidence*, 339-341
- Expert agency reports*, 341-342
- Exposure*, 337-339
- Findings*, 343-344

**Reduced radiation**

- Computed tomography, cancer risk in later life*, 84-85  
*(News & Views)*

**Relaxation techniques**

- Nausea and vomiting management*, 245

**Renal disease**

- Comorbidity in geriatric oncology research*, 331

**Retching.** See **Nausea, vomiting, and retching**

**Retinoids**

- Oral mucositis*, 305-306

**S**

**Salvage therapy**

- Multiple myeloma*, 283

**Screening.** See **Cancer screening**

**Self-care**

- Nausea and vomiting*, 238-240

**Self-examination**

- Breast cancer, importance of*, 268-270 (*News & Views*)

Volume 51 • Number 6 • November/December 2001

383

*Melanoma, improves survival of second,* 207–208  
*(News & Views)*

**Sigmoidoscopy.** See Flexible sigmoidoscopy  
**Silver nitrate**

*Oral mucositis,* 306

**Smoking.** See Tobacco smoking

**Sodium alginate**

*Oral mucositis,* 306

**Soy foods**

*Nutrition,* 167

**Spiral computed tomography**

*Lung cancer, ACS early detection guidelines,* 63, 64

**Sputum cytology**

*Lung cancer, ACS early detection guidelines,* 61–62

**Staging**

*Cervical cancer, clinical versus surgical staging,* 102–104

*Gallbladder cancer,* 356

*Multiple myeloma,* 276–277

**Steroids**

*Multiple myeloma,* 282

**Sucralfate**

*Oral mucositis,* 305

**Surgical management**

*Cervical cancer,* 102–108

**Surveillance, Epidemiology, and End Results (SEER) Program**

*Childhood cancer,* 121, 129

**Survivors.** See also Nutrition

*Nutrition advice,* 151–152 (Editorial), 153–181

## T

**Tamoxifen therapy**

*Breast cancer,* 317

*Endometrial cancer, ACS early detection guidelines,* 55, 56–57

**T-cell vaccine**

*Cervical cancer,* 110

**Teas**

*Nutrition,* 167

**Technology transfer**

*Cancer statistics, directions in,* 12 (Guest Editorial)

**Thalidomide**

*Multiple myeloma,* 278–279, 283

**Tobacco smoking**

*Advertising and children,* 324–326 (News & Views)

*Breast reconstruction surgery complications,* 149–150  
*(News & Views)*

*Cancer prevention, study on,* 265–267 (News & Views)

*Colorectal cancer risk,* 9 (News & Views)

*Lung cancer,* 195

*Media,* 142–144

*Radon exposure,* 341

**Transforming growth factor-β3**

*Oral mucositis,* 306

**Transvaginal ultrasound (TVU)**

*Endometrial cancer, ACS early detection guidelines,* 55–56

**Tumor burden**

*Nausea and vomiting,* 237–238

## U

**Ulcerative colitis**

*Colorectal cancer, ACS early detection guidelines,* 51

**United States Environmental Protection Agency (EPA)**

*Arsenic,* 256

*Diesel exhaust,* 196

*Radon exposure,* 338, 339, 342

**United States Food and Drug Administration (FDA)**

*Brain tumor risk, cellular phone and,* 137–141

**Uridine**

*Oral mucositis,* 309

## V

**Vaccination**

*Cancer prevention, study on,* 265–266 (News & Views)

*Cervical cancer,* 109–110

**Varicella zoster virus**

*Oral mucositis,* 302–303

**Vegetarian diets**

*Nutrition,* 163

**Viral infection**

*Oral mucositis,* 302–303

**Vitamin C.** See also Nutrition

*Genotoxic lipid metabolites promoted by, complementary and alternative methods (CAM),* 316–317

*Radiation proctitis symptoms diminished by,* 209–210  
*(News & Views)*

**Vitamin E.** See also Nutrition

*Oral mucositis,* 306

*Radiation proctitis symptoms diminished by,* 209–210  
*(News & Views)*

**Vomiting.** See Nausea, vomiting, and retching

## X

**X-ray.** See Chest X-ray

